Juridical Foundation the Chemo-sero-therapeutic Research Institute

The Chemo-sero-therapeutic Research Institute

Km Biologics Co., Ltd.

Teijin Limited

Teijin Pharma Limited

Hisamitsu Pharmaceutical Company, Inc.

Kumamoto University

Mitsubishi Kagaku Iatron, Inc.

Kumamoto Health Science University

Mitsubishi Chemical Medience Corporation

National University Corporation Kumamoto University

Curedisc Corporation

Masaki Hirashima

Hiroaki Maeda

Chikateru Nozaki

Ryoichi Kawamura

Susumu Honda

Hiroaki Kaneko

Makoto Satake

Takayuki Imamura

Hiroshi Nakatake

Kentaro Fujinaga

Yukako Kageyama

Ayuko Yamaguchi

Yusuke Akiyama

Wataru Morikawa

Takeshi Naruse

Akitoshi Oono

Kenji Soejima

Takeshi Goto

Kazuyoshi Kaminaka

Junichi Matsuda

Takayoshi Hamamoto

Katsuhiko Akiyama

Norio Akaike

Takumi Sasaki

Shintaro Kamei

Tomoko Ono

Sachio Okuda

Reiko Matsuyama

Kazuo Takahama

Wataru Hattori

Yoichi Sakata

Hideki Takeo

Ryoko Wada

Megumi Imuta

Sachie Ogawa

Misako Umehashi

Asami Shindome

Kiyotaka Suenaga

Akihiro Meta

Takashi Kuwana

Ayumi Ishiwari

Yukiko Kimura

Souichirou Katou

A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material.

Formed sheet product and hemostatic material

A method for monomerization of MMP-7 aggregates is provided. A method for monomerization of MMP-7 aggregates which comprises treating MMP-7 aggregates with a buffer solution comprising a monovalent cation chloride (sodium chloride, potassium chloride, etc.) at a low concentration or with a buffer solution not comprising a monovalent cation chloride, a process for preparing MMP-7 which involves said method for monomerization, and a (pharmaceutical) composition comprising MMP-7 in the aforementioned buffer solution. In case that a (pharmaceutical) composition comprising MMP-7 at a low concentration is prepared, the aforementioned buffer solution comprising sugar alcohols or sugars is used.

Method for monomerizing matrix metalloproteinase 7 (MMP-7) aggregate

A modified transposon vector and a method for introducing a foreign gene into a cell are provided. A modified transposon vector wherein a nucleic acid fragment having the following features (a)-(b) or (a)-(c) is inserted; a cell expressing a foreign gene obtained by introducing said vector into chromosomal DNA of a cell line or an ontogenetic cell and further introducing an expression cassette of a foreign gene into the chromosomal DNA; a genetically recombined animal generated by using said cell (in case of an ontogenetic cell); and a method for producing a foreign protein from said cell and said genetically recombined animal:

Modified transposon vector and its use

A process for preparing an inclusion body-forming protein is provided. A nucleic acid fragment having a nucleotide sequence coding for a modified alkaline phosphatase signal peptide (modified APSP) where leucine at the 13th position in the amino acid sequence shown in SEQ ID NO: 1 is substituted with proline and/or alanine at the 21st position is substituted with the other amino acid, downstream of which nucleotide sequence is bound a nucleotide sequence of a gene of a protein of interest is also provided.

Process for preparing inclusion body-forming protein

The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as 'FXIa'), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.

Plasma protein effective for suppressing cough

A method of detecting thrombosis or the degree of thrombophilia by measuring a von Willebrand factor cleaving protease, and a kit for detecting thrombosis or the degree of thrombophilia, comprising an antibody or a fragment thereof specifically binding to a von Willebrand factor-cleaving protease, are disclosed. The detection method and the detection kit have an excellent convenience, rapidity, and specificity.

Method of detecting thrombosis by measuring von Willenbrand factor-cleaving protease

A peptide fragment or a series of peptide fragments containing one or more selenocysteine that has a lowered toxicity than selenocystine and that exhibits a cytotoxicity-inhibitory activity. The peptide fragment or a series of peptide fragments according to the present invention has preferably the amino acid sequence from 260th to 362nd amino acid residues from the C-terminal of selenoprotein P, or said amino acid sequence with one or several amino acid residues therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences. A screening method for a peptide fragment having the cytotoxicity-inhibitory activity is also provided.

Peptide having cytotoxicity inhibitory activity and method of screening these peptide having cytotoxicity inhibitory activity

A novel medicament for treating neurodegenerative diseases, especially for ameliorating dyskinesia, comprising as an active ingredient selenoprotein P and/or a peptide fragment or a series of peptide fragments derived from said protein is provided. The novel medicament for treating neurodegenerative diseases, especially for ameliorating dyskinesia, according to the present invention is suitably applicable to diseases with decrease in motor function.

Method for ameliorating dyskinesia

The present invention provides a peptide fragment or a series of peptide fragments having a cell death-inhibitory activity, having the amino acid sequence consisting of 103 amino acid residues at the C-terminal of selenoprotein P, or having said amino acid sequence with one or several amino acid residues therein being deleted, substituted or added, or having a partial sequence of either of the above amino acid sequences, a medicament for treatment comprising said peptide fragment or a series of peptide fragments, an antibody to said peptide fragment or a series of peptide fragments, and a method for screening a cell death-inhibitory activity using said peptide fragment or a series of peptide fragments. The preferable peptide fragment or a series of peptide fragments of the present invention has the amino acid sequences shown in SEQ ID NO: 1 and/or SEQ ID NO: 2 or has a partial sequence thereof.

Antibodies to peptide fragments having cell death-inhibitory activity

Peptide fragments having cell death inhibitory activity

Growing community of inventors

Kikuchi, Japan

Masaki Hirashima